Get Started for FREE
Sign up with Facebook Sign up with X
I don't have a Facebook or a X account
Novo Nordisk and devices firm Abbott have announced a digital partnership that aims to make diabetes management easier.
VIENNE (TICpharma) - Alors que l'engouement pour la blockchain de la part des laboratoires pharmaceutiques ne fait plus aucun doute, Pascal Bouquet, directeur monde en charge de la technologie, de l’architecture et du numérique du laboratoire suisse Novartis, a jugé que la technologie "transformera le secteur pharmaceutique dans les 10 ans".
Sanofi nomme Ameet Nathwani au poste de Chief Digital Officer
Le Dr Ameet Nathwani continuera d'exercer les fonctions de Vice-Président Exécutif, Chief Medical Officer
Paris - Le 12 février 2019 - Sanofi annonce la nomination du docteur Ameet Nathwani au poste de Chief Digital Officer, en complément de ses responsabilités actuelles de Vice-Président Exécutif, Chief Medical Officer.
Le Dr Nathwani aura pour mission de renforcer la stratégie de Sanofi en matière d'intégration des technologies numériques et de la science médicale, afin d'améliorer la prise en charge des patients
L'agence conseil en communication digitale Ultramedia a publié un baromètre qui classe les laboratoires pharmaceutiques selon leur capacité à exercer un L'agence Ultramedia a publié un baromètre qui classe les laboratoires pharmaceutiques selon leur capacité à exercer un leadership d’opinion.
Ads for prescription drugs appeared 5 million times in just one year, capping a recent surge in U.S. medical marketing, a new analysis found. The advertisements for various medicines showed up on TV, newspapers, online sites and elsewhere in 2016. Their numbers soared over 20 years as part of broad health industry efforts to promote drugs, devices, lab tests and even hospitals. The researchers estimated that medical marketing reached $30 billion in 2016, up from $18 billion in 1997. Spending on consumer-focused ads climbed fastest. But marketing to doctors and other health professionals still grabbed the biggest share with the bulk of it paying for free drug samples.
A l’occasion de la publication de son bilan 2017 des entreprises du médicament, le LEEM vient de dresser un panorama du marché pharmaceutique mondial. Découvrez le classement des dix produits les plus vendus dans le monde en 2017 ainsi que les principales classes thérapeutiques.
London, April 5th, 2018.
The 'Corporate Reputation of Pharma in 2017' report is based on the findings of a PatientView November 2017-February 2018 survey exploring the views of 1,330 patient groups worldwide. The report provides feedback (from the perspective of these patient groups) on the corporate reputation of the pharma industry during 2017, as well as on the performance of46 pharma companies at 12 key indicators that influence corporate reputation.
The Corporate-Reputation survey is now in its 7th edition—thus, 7 years of historical data are available. In addition, we incorporated several important new indicators of corporate reputation into the 2017 survey—to reflect the changing, and more demanding, relationships that now exist between patient groups and pharma companies.
In 2017, patient-group attitudes towards pharma improved, after plummeting in 2016.
43% of respondent patient groups thought that the pharma industry had an "Excellent" or "Good" corporate reputation in 2017—against 38% of patient groups saying the same in 2016.
In 2017, respondent patient groups ranked the pharma industry 3rd overall for corporate reputation out of 9 healthcare-industry sectors, the other sectors being: biotech; generic-drugs industry; health insurers (for-profit, and not-for-profit); medical-device industry; private-sector healthcare; and retail pharmacy. In 2016, patient groups ranked the pharmaceutical industry just 5th out of 9 healthcare sectors.
PHARMA ALSO IMPROVED IN KEY ACTIVITIES IN 2017 ...
2017's respondent patient groups rated pharma as improving its performance over 2016 at three areas of activity important to patients and patient groups: patient centredness (35% of the patient groups stated that the industry was “Excellent” or “Good” at this activity, compared with just 26% in 2016); integrity (31% described the industry as “Excellent” or “Good” at this activity, compared with just 28% in 2016); and in services provided ‘beyond the pill' (27% thought industry “Excellent” or “Good” at this, compared with just 20% in 2016).
BUT ...
Respondent patient groups were far more negative in 2017 than in 2016 about several other pharma-industry activities. For instance, only 48% of 2017’s respondent patient groups judged pharma “Excellent” or “Good” at being innovative (down from 59% in 2016; which, in turn, was down from 69% in 2015). The 2017 figure is the lowest-reported percentage for the pharma industry's capacity to innovate since 2011 (when PatientView's Corporate-Reputation surveys began). Equally negative were 2017 attitudes towards the industry’s ability to make high-quality products. Only 57% of respondent patient groups in 2017 saw pharma as “Excellent” or “Good” at making high-quality products (down from 64% in 2016—which, was, in itself, also down from 72% in 2015). Again, the 2017 figure is the lowest-reported percentage for pharma and high-quality products since 2011.
Patients, when working with pharma and actually knowing the pharma company they work with, see developments to collaboration with them! Inspiring results from those who care! ;-)
http://www.patient-view.com/--corp-rep-reports-published-2018.html
Selon les résultats de la dernière enquête annuelle Emploi du Leem, la stabilisation des effectifs de l’industrie pharmaceutique en France se confirme. Avec 98 786 salariés recensés à fin 2016, soit une progression des effectifs de 0,1 %, l’industrie pharmaceutique bénéficie d’une trajectoire de l’emploi légèrement plus favorable que celle observée dans l’ensemble de l’industrie manufacturière (- 0,9 %).
The application of existing and new theories, translating theory into real-world solutions, is key to sustainable HCP behaviour change.
At next month’s Patient Summit Europe (19-20 October, London) find out how you can be more than a trusted partner – get yourself on the same side as your patients, and deliver sophisticated advocacy that fights their cause.
Patient advocacy groups and pharma companies have the same ultimate goal – better health outcomes – but managing these relationships needs care on both sides.
To give you an insight into the level of discussion you can expect at the summit, we spoke with:
- Nisith Kumar, Director, Global Patient Affairs, Pfizer
- Ann Kwong, Founder and CEO, TREK Therapeutics
- Lynn Bartnicki, Patient advocate, Living Beyond Breast Cancer
Read the article ‘Dancing to the same tune?’ here: https://goo.gl/hgVVms
Kind regards,
Cintia Hernandez Marco
“Some drug companies are really focused on patients, and some don’t have a clue.” Lynn Bartnicki, patient advocate
- a quote from the report of Eyeforpharma.
Good to see some words from pharma and patient advocates published.
Even better to follow and read one of the many publications about the pharma and patient groups' relations: a trying but difficult engagement
You can look at the patient perspective in "pharma corporate reputations",
or overviews of the patient movement. A study about pharma and the connected patient. And above all: check your own credibility as a pharma company in the eyes of patients: your bespoke data on your company, for its different affiliations and therapy areas, based on 6 years of global data on corporate reputation in the perspective of patients and patient groups.
“Some drug companies are really focused on patients, and some don’t have a clue.” Lynn Bartnicki, patient advocate
- a quote from the report of Eyeforpharma.
Good to see some words from pharma and patient advocates published.
Even better to follow and read one of the many publications about the pharma and patient groups' relations: a trying but difficult engagement
You can look at the patient perspective in "pharma corporate reputations", or at overviews of the patient movement.
A study about pharma and the connected patient. And above all: check your own credibility as a pharma company in the eyes of patients: your bespoke data on your company, for its different affiliations and therapy areas, based on 6 years of global data on corporate reputation in the perspective of patients and patient groups.
PARIS (TICpharma) - Sanofi va ouvrir avant la fin de l'année sur son campus de Gentilly (Val-de-Marne) un laboratoire "100% dédié à l'e-santé" intitulé "39Bis", ont annoncé jeudi à la presse le directeur de Sanofi France, Guillaume Leroy, et la directrice de l'innovation, Isabelle Vitali.
Oltre i follower .... l'Engagement Index.
It is calculated by a statistical analysis on engagement, reach, demographics, network and othe
This report profiles the NASs launched in the U.S. over the past 20 years and measures the length of a molecule’s lifetime from patent filing to launch and eventual patent expiry. It also explores the significant variations in this lifetime when viewed by molecule characteristics such as therapy area, orphan drug status, and the type of companies involved in the development and marketing.
Take a look at some of the coverage from the event in The Scientist, American Journal of Managed Care, and The Pharma Letter.
Relevant Insights into the development in lifetime characteristics of biopharmaceutical substances: only relative few outliers that make a quick retunr about 1$ billion a year (within 5 years after launch) Modest levels of average return (less than $100 billion) a year for 62% of launches in the past 20 years. The commercial returns for a small number of outlier molecules areoutsized but rare, while a substantial number of molecules baing launches achive levels of commercial success that fall far below threshold levels of economic return.
Take a look at some of the coverage from the event in The Scientist, American Journal of Managed Care,
Pharmaceutical manufacturers, payers and healthcare providers (HCPs)—as well as a host of tech-focused newcomers—are exploring digital programs that complement standard therapies and hold promise to keep patients healthier and produce better outcomes. Known as “beyond-the-pill” or “around-the-pill” services, they have been a long time coming, and may finally be gaining traction, according to a new eMarketer report,“US Healthcare Beyond the Pill: Digital Tech and New Partnerships Bring New Life to the Industry” (eMarketer PRO customers only).
For the past several years, healthcare and pharma firms have been trying, with mixed success, to step up their beyond-the-pill programs. Early efforts included basic informational websites and simple apps designed to provide information about medical conditions and therapies.
“When the pharma industry first moved into digital technology, it was primarily in the marketing space, leveraging things like websites or HCP portals to share product information and to educate,” said Amy Landucci, head of digital medicine at Novartis. “But in the last three years, we’ve seen a pretty big shift away from just doing digital marketing—though it’s still very important—to looking at how technology can help enhance patient outcomes.”
Today’s beyond-the-pill solutions can collect, monitor and analyze health-related information, track patient activity, improve medication adherence, provide personalized decision support, predict medical crises and streamline medical care using a variety of advanced computing techniques. Mobile technology, the IoT and AI are three of the technologies making this possible.
Read one here
Save
Pharma started about thinking in terms of servicing health care "beyond the pill" in about 2000. Today developments have been increased by ideas of 'integrated care' and "precision medicine" the latest concept indicates fine tuning of medications to personal physical and genome conditions. Diagnostics are all in the game, that is. But a study in which I participated [ http://1.eyeforpharma.com/LP=5676 ] made clear that development and creation is one, servicing and delivering is two. Partnerships for example are unavoidable is one in in the game for sustainable business.
Like in most industries, players in the pharmaceutical world get a boost when customers the world over feel that they are innovators, act responsibly and are, generally speaking, a force for good. Recently a survey was published scoring exactly how good people in developed countries all over the world feel about big pharma.
Just discovered the global pharma reputation ranking by the Reputation Institute. Based on 7 dimensions of reputation, defined by the institute, the companies were evaluated by respondents around the world. These were "Products&Services, Innovation, Workplace,Governance, Citizenship, Leadership and Performance". See the RepTrak Institute here
PatientView however has studied the global reputation of pharma companies in the perspective of patients and patient groups since 2011! See here. Their respondents were also distinguished by those who state to be familiar with a company and those who really worked with a company, which generates interesting data! PatientView is now preparing data such that companies can retrieve their bespoke ranking data to see how their reputation in the perspective of patients can further be improved
NOTE: One trend pharmaceutical companies should take note of is the tendency of respondents to be uninformed or neutral about what companies actually do in certain areas. According to the survey, 12% of respondents did not have knowledge or opinion about the companies’ overall performance. Meanwhile, 11% had no knowledge of companies’ citizenship activities (promoting good causes and protecting the environment) and 14% didn’t know anything about the workplaces of the firms they were asked to score.
Successful business model innovation requires an understanding of how business models evolve.
Many attempts at business model innovation fail. To change that, executives need to understand how business models develop through predictable stages over time — and then apply that understanding to key decisions about new business models.
Understanding the interdependencies in a business model is important because those interdependencies grow and harden across time, creating another fundamental truth that is critical for leaders to understand: Business models by their very nature are designed not to change, and they become less flexible and more resistant to change as they develop over time. Leaders of the world’s best businesses should take special note, because the better your business model performs at its assigned task, the more interdependent and less capable of change it likely is. The strengthening of these interdependencies is not an intentional act by managers; rather, it comes from the emergence of processes that arise as the natural, collective response to recurrent activities. The longer a business unit exists, the more often it will confront similar problems and the more ingrained its approaches to solving those problems will become. We often refer to these ingrained approaches as a business’s “culture.”
Great article about business model innovation. I was struck by the resemblances of errors made at introducing new value added services to pharmaceuticals, "beyond the pill". The same may possibly be expected by the new "hype" (?) about patient centricity: in my mind doing things without reflection about what it is: ending up in webinars/conferences existing mainly of either pharma staff in which they share their ignorance, or even in pharma staff added with a patient or patient representative, in which the patient is commonly canonized (as in 'sainted'): understandable but not a functional way of developing new trends in a company, let alone a new trend in a business sector..
See here what patients really have to say about corporate pharma companies and its patient "centricity": PatientView.com
Google has announced changes to how it will rank sites in mobile search, penalising some websites. Here's what pharma digital marketers need to know.
mHealth brings opportunities to better understand how conditions impact everyday life and develop solutions that work.
IBM, Pfizer launch joint experiment to help measure Parkinson’s symptoms using IoT and analytics
CONSULTER LE PROGRAMME DU #FCSante ! Ne manquez pas cette journée de conférences le vendredi 27 novembre ! Vous souhaitez y assister ? Inscrivez-vous ! Vous avez -30 ans ou êtes étudiant ?
NOUVEAUTÉ : TARIF SPÉCIAL
Inscrivez-vous ! 09h00 Ouverture du Festival et accueil des participants 11h00 Ouverture par Dominique Noël, Présidente du Festival de la Communication Santé 11h15
12h15
Plusieurs expériences pilotes sont lancées en France. La parole des patients participe au renouveau du parcours de soins.
Animée par Éric de Branche, Directeur de la Communication - Leem
• Isabelle Delattre, Créatrice des prix Paroles de Patients et Talents de Patients
• Marine de Nicola, Chanteuse et "survivante" du cancer
• Georges Elia Sarfati, Professeur des Universités, analyste existentiel, philosophe et linguiste
• Alain Toledano, Oncologue et Radiothérapeute
• Pr Catherine Tourette-Turgis, Fondatrice de l’Université des Patients, Faculté de Médecine, Université Pierre et Marie Curie (Paris) 12h15 - 14h00 Déjeuner - networking 14h00
14h05 SPEED VISION : RÉSEAUX SOCIAUX ET SANTÉ... CE QUE SHAKESPEARE PEUT NOUS APPRENDRE
Lionel Reichardt, Fondateur de Pharmageek 14h05
15h05
À l’heure du patient centric, les entreprises de santé doivent-elles devenir des marques média et redéfinir leur communication auprès du patient-consommateur de santé ?
Animée par Éric Phélippeau, Président de la FNIM
• Nadia Auzanneau, Directrice d’OpinionWay Santé, dévoilera en avant-première les chiffres clés de l’enquête réalisée en partenariat avec la FNIM / FCS
• Valérie Perruchot Garcia, Directeur des Affaires Publiques et de la Communication - Janssen France
• Sébastien Sillon, Directeur de la Communication, Mécénat et RSE - Laboratoires Expanscience
• Isabelle Morin, Directeur Marketing et Communication - Biogaran 15h05
15h10 SPEED VISION : LES 3 ENJEUX CLÉS DU BIG DATA EN SANTÉ ?
Emmanuelle Pierga, Directrice de la Communication d’Orange Healthcare
David Réguer, Directeur de RCA Factory Healthcare 15h10
16h10
En miroir de la conférence mondiale sur le climat tenue à Paris en décembre, Pharmaceutiques organise une table ronde sur l’impact des problématiques environnementales en matière de santé. Effets du climat et de la pollution sur l’état sanitaire des populations, incidence environnementale des activités de production des soins, responsabilité sociale et environnementale des entreprises de santé, gestion des déchets à risque… diverses questions seront abordées.
Animée par Hervé Réquillart, Directeur de la Rédaction - Pharmaceutiques
• Delphine Caroff, Directeur des Affaires Européennes, relations extérieures et RSE - Leem
• Béatrice Parance, Professeur agrégée de droit privé, Université Paris 8 Vincennes - Saint-Denis
• Philippe Le Jeunne, Directeur Médical - IMS Health France 16h10
16h15 SPEED VISION : HUMANISME ET NOUVELLES TECHNOLOGIES : OXYMORE OU SYNERGIE ?
Cécile Monteil, Directeur Médical à Ad Scientiam, Fondatrice d’Eppocrate, Docteur, Hôpital Robert Debré (Paris) 16h15 - 16h45 Pause - networking 16h45
16h50 SPEED VISION : LE MÉDECIN ET LE GEEK... REGARDS CROISÉS SUR LA SANTÉ CONNECTÉE
Les dernières innovations d’objets connectés santé
Lionel Reichardt, Fondateur de Pharmageek
Cécile Monteil, Directeur Médical à Ad Scientiam, Fondatrice d’Eppocrate, Docteur, Hôpital Robert Debré (Paris) 16h50
17h50
Animée par Jérôme Vincent, Journaliste Le Point
• Pr André Grimaldi, Professeur Émérite d’Endocrinologie-Diabétologie, CHU de La Pitié - Salpêtrière (Paris)
• Christophe Jacquinet, Président - Santéliance Conseil 17h50
18h00
19h00 Cocktail
20h00 Dîner
Vous souhaitez y assister ? Inscrivez-vous ! Vous avez -30 ans ou êtes étudiant ?
NOUVEAUTÉ : TARIF SPÉCIAL
Inscrivez-vous !
Et n’oubliez pas, il est encore temps de soumettre vos plus belles campagnes !
Communication santé publiqueCommunication produit grand publicCommunication médicaleCommunication hospitalièreCommunication associativeCommunication patients et leurs aidantsCommunication corporateCommunication santé en entrepriseStart-up
Vous êtes prêt à relever le défi ?
Inscrivez-vous !
For months and months speculation was rife about the Apple Watch (or iWatch as was the expected moniker) and the possible implications and applications for healthcare. Then we had the 9th March launch event in San Francisco and theApple Watch seemed to sink like a lead balloon in the minds of health technology enthusiasts. This was aided by articles such as the one in the Wall Street Journal that claimed much of the exciting health sensor technology had been scrapped and asked: What Exactly Is an Apple Watch For? (Subscription required)
I believe that technology only becomes socially interesting when it becomes technologically boring. We can only really impact health at scale when we utilise technology that has true mainstream reach. However I feel there are still a number of key reasons the Apple Watch is worth thinking about for healthcare broadly, and pharmaceutical companies specifically. Here are five reasons pharma should care as we approach the April 24th Apple Watch launch date
INTERVIEW: Accenture's David Logue talks digital pharma
PharmaTimes
DL: Pharma marketing organisations are often set up with a dependency on colleagues in the technology function to deliver digital experiences.
A l'occasion de la Journée mondiale de la tuberculose, le Janssen Health Policy Centre a dévoilé mardi un tableau de bord numérique permettant de parcourir et de comparer les données sanitaires de 15 maladies parmi les plus répandues dans les 28 États membres de l'Union Européenne (UE), un outil d'analyse unique en son genre.
When it comes to researching diseases, seniors don't turn to—or trust—pharmaceutical companies very much. If pharma companies want to change this, they'll need seniors' doctors, friends and family members to sing their praises, as recommendations are the top factors that would motivate those 66 and older to visit pharma-sponsored websites.
voices of senior customers matter also...
Sanofi a entamé le recrutement de 700 patients diabétiques pour tester une application leur permettant de calculer en temps réel leur dose...
Pharma Manager & Geek ... #hcsmeu #hcsmeufr #health20fr
http://www.scoop.it/t/pharma-geek
http://www.tikimee.com/lionel-reichardt
